The purpose of the study is to evaluate the drug levels, safety and tolerability of BMS-986368 in healthy Chinese participants
Participants must be healthy male or non-pregnant and non-nursing female (as assigned at birth).
Participants must be of Chinese ethnicity (both biological parents should be ethnically Chinese).
Participants must have BMI of 18.0 kg/m2 to 28.0 kg/m2, inclusive and body weight of ≥ 50 kg.
Participants must not have personal or first-degree family history of clinically significant psychiatric disorder, including, but not limited to, schizophrenia, psychosis, bipolar disorder, major depressive disorder, generalized anxiety disorder, obsessive-compulsive disorder, and post-traumatic stress disorder. Participants with a history of anxiety may be enrolled at the discretion of the investigator.
Participants must not have an active or prior history of stroke, chronic seizures, or major neurological disorders or has first-degree family relative who was diagnosed with these disorders below the age of 65 years.
Other protocol-defined Inclusion/Exclusion criteria apply.
Parallel
BMS-986368
DrugSpecified dose on specified days
BMS-986368-matching Placebo
Other interventionSpecified dose of specified days
Maximum observed concentration (Cmax)
Time of maximum observed concentration (Tmax)
Area under the concentration-time curve (AUC)
Number of participants with adverse events (AEs)
Number of participants with serious adverse events (SAEs)
Number of participants with clinically significant vital sign measurements
Number of participants with clinically significant 12-lead electrocardiogram (ECG) examinations
This trial is not recruiting at the moment. You can still explore other options:
